Condition

Radiotherapy; Adverse Effect, Dermatitis or Eczema

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting0

Common interventions4

Lead sponsors shown3

Clinical trials

3 shown

Evaluation of Mepitel Film® in Preventing Epidermitis in Patients Receiving Radiation Therapy for Breast CancerNCT04149522 · 2020-01-15

TERMINATED

Toxicity and Outcome of Whole Breast Hypofractionated Radiotherapy: a Single Institution ExperienceNCT03077191 · 2016-11-01

ACTIVE_NOT_RECRUITING

Laser InGaAlP (660Nm) to Prevent Radiodermatitis in Breast Cancer Patients Submitted to Radiation TherapyNCT02003599 · 2014-05-01

COMPLETED

Common interventions

Laser therapyDEVICE1 Mepitel Film®DEVICE1 PlaceboDEVICE1 Quality of life measurementOTHER1

Leading sponsors

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) 1 IRCCS San Raffaele 1 Universidade do Vale do Sapucai 1

Trial status mix

ACTIVE_NOT_RECRUITING1

COMPLETED1

TERMINATED1

Phase mix

NA1

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.